Colorectal cancer vaccine: Targeted Diagnostics & Therapeutics

Drug Profile

Colorectal cancer vaccine: Targeted Diagnostics & Therapeutics

Latest Information Update: 07 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Thomas Jefferson University
  • Developer Targeted Diagnostics and Therapeutics; Thomas Jefferson University
  • Class Cancer vaccines
  • Mechanism of Action Guanylate cyclase C modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Colorectal cancer

Most Recent Events

  • 22 Nov 2016 Viral Gene plans to apply to the US FDA for Orphan Drug Designation for the cancer vaccine
  • 22 Nov 2016 Targeted Diagnostics & Therapeutics and Viral gene plan a clinical trial for Colorectal cancer in South Korea
  • 22 Nov 2016 Targeted Diagnostics & Therapeutics and Viral gene plan a phase II trial for Colorectal cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top